Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 05, 2024 16:05 ET
|
Chimerix, Inc.
DURHAM, N.C., July 05, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on July 1, 2024, the Compensation Committee of Chimerix’s Board of Directors granted inducement awards to...
Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference
May 30, 2024 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., May 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...
Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update
May 01, 2024 07:00 ET
|
Chimerix, Inc.
– Dordaviprone (ONC201) ACTION Study Progressing; Reiterates Expectations for Interim Overall Survival (OS) Data in 2025 and Final OS Data in 2026 – – No Dose Limiting Toxicity in ONC206 Phase 1...
Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024
April 24, 2024 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., April 24, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 16, 2024 16:05 ET
|
Chimerix, Inc.
DURHAM, N.C., April 16, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX) today announced that on April 10, 2024, the Compensation Committee of Chimerix’s Board of Directors granted inducement awards...
Chimerix Appoints Marc D. Kozin to Board of Directors
March 21, 2024 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update
February 29, 2024 07:00 ET
|
Chimerix, Inc.
– ONC201 ACTION Study Progressing; Reiterate Interim OS Data Expected in 2025, Final OS Data Expected in 2026 – – Phase 2 ONC201 Data Published in Peer-Reviewed Journal of Clinical Oncology – – $204...
Chimerix to Present at TD Cowen 44th Annual Health Care Conference
February 27, 2024 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024
February 22, 2024 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix Appoints Lisa Decker to Board of Directors
December 29, 2023 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Dec. 29, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...